

Manuscript Number: IJP-D-20-01635R2

Title: Inclusion complexes of tricyclic drugs and β -cyclodextrin:
inherent chirality and dynamic behaviour

Article Type: VSI: T. Loftsson 70th Birthday

Section/Category: Pharmaceutical Nanotechnology

Keywords: NMR spectroscopy, Tricyclic drugs, Host-guest complex, Chiral
recognition, Dynamics

Corresponding Author: Dr. Maria Enrica Di Pietro, Ph.D.

Corresponding Author's Institution: Politecnico di Milano

First Author: Maria Enrica Di Pietro, Ph.D.

Order of Authors: Maria Enrica Di Pietro, Ph.D.; Monica Ferro, Ph.D.;
Andrea Mele, Prof.

Abstract: Amitriptyline (AMT) and cyclobenzaprine (CBZ) are tricyclic drugs used as antidepressant and muscle relaxant, respectively. They show inherently chirality, i.e. they are chiral due to the lack of any symmetry element. As they are used as racemic mixture, diastereomeric inclusion complexes are formed via encapsulation in homochiral β CD. In this work we show that a suitable combination of NMR methods easily provides details on the chiral recognition, geometry of complexation, rotational dynamics and spatial proximity of selected atom pairs. In particular, we show that ^{13}C NMR can be used to unambiguously assess chiral recognition, demonstrating a higher performance over ^1H NMR. The mole fraction of the bound drug and the association constant can be worked out through diffusion experiments, whereas the combination of non-selective, selective and bi-selective relaxation spectra gave insights into the rotational motion of the complexed drug and the spatial proximity of selected proton pairs. The toolkit here proposed provides a thorough characterization of CD/drug inclusion complexes from a physicochemical point of view. This can constructively complement the conventional pharmacological and pharmacokinetic experiments, and can shed light on the understanding of CD/drug formulations.



POLITECNICO MILANO 1863

Milan, August 12, 2020

Dear Professor Alvarez-Lorenzo,

I am glad to submit the revised version of our manuscript "Inclusion complexes of tricyclic drugs and β -cyclodextrin: inherent chirality and dynamic behaviour" by Maria Enrica Di Pietro, Monica Ferro and Andrea Mele, for consideration for publication in the *Special Issue of the International Journal of Pharmaceutics in Honor of Professor Thorsteinn Loftsson on the Occasion of His 70th Birthday*.

As required, references are formatted according to IJP style and abstract is one single paragraph.

Thank you for your consideration.

Yours sincerely,



Maria Enrica Di Pietro, PhD

Responses to Reviewers' Comments:

Reviewer #2: It could be accepted

Authors' reply:

We thank Reviewer 2 for her/his appreciation of the work.



1 Inclusion complexes of tricyclic drugs and β -cyclodextrin: inherent chirality and 2 dynamic behaviour

3 Maria Enrica Di Pietro,^{*,a} Monica Ferro,^a and Andrea Mele^{*,a,b}

4

5 ^a Department of Chemistry, Materials and Chemical Engineering "G. Natta", Politecnico di Milano, Piazza L.
6 da Vinci 32, 20133 Milano, Italy.

7 ^b Istituto di Scienze e Tecnologie Chimiche (SCITEC-CNR), Via A. Corti 12, 20133 Milano, Italy.

8

9 Abstract

10 Amitriptyline (AMT) and cyclobenzaprine (CBZ) are tricyclic drugs used as antidepressant and muscle
11 relaxant, respectively. They show inherently chirality, i.e. they are chiral due to the lack of any symmetry
12 element. As they are used as racemic mixture, diastereomeric inclusion complexes are formed via
13 encapsulation in homochiral β CD. In this work we show that a suitable combination of NMR methods easily
14 provides details on the chiral recognition, geometry of complexation, rotational dynamics and spatial
15 proximity of selected atom pairs. In particular, we show that ¹³C NMR can be used to unambiguously assess
16 chiral recognition, demonstrating a higher performance over ¹H NMR. The mole fraction of the bound drug
17 and the association constant can be worked out through diffusion experiments, whereas the combination
18 of non-selective, selective and bi-selective relaxation spectra gave insights into the rotational motion of the
19 complexed drug and the spatial proximity of selected proton pairs. The toolkit here proposed provides a
20 thorough characterization of CD/drug inclusion complexes from a physicochemical point of view. This can
21 constructively complement the conventional pharmacological and pharmacokinetic experiments, and can
22 shed light on the understanding of CD/drug formulations.

23

24 Keywords

25 NMR spectroscopy – Tricyclic drugs – Host-guest complex - Chiral recognition - Dynamics

26

27 1. Introduction

28 Cyclodextrins (CDs) are a family of macrocyclic oligosaccharides that derive from the enzymatic degradation
29 of starch and consist of glucopyranose units in the ⁴C₁ chair conformation connected with $\alpha(1-4)$ glycosidic

30 bonds (Crini, 2014; Kurkov and Loftsson, 2013). The most extensively used and studied CDs are α -, β - and γ -
31 CD, which contain six, seven, and eight glucopyranose units, respectively. CDs have a doughnut-shaped
32 structure with all secondary hydroxyl groups O2'-H and O3'-H located on the wider edge, and all primary
33 hydroxyl groups O6'-H on the narrower side, and with a characteristic hydrophobic cavity coated by non-
34 polar C3'-H, C5'-H groups and ether-like O4' atoms (see Fig. 1 for numbering) (Brewster and Loftsson,
35 1996). Acting as hosts, CDs accommodate various hydrophobic compounds or the hydrophobic moieties
36 present in the molecules (guests) inside the inner cavity to form non-covalently bonded inclusion
37 complexes. The CD's cavity size and the structural conformation and size of the guest are the parameters
38 that mostly affect the formation of the host-guest complex. β CD is the most widely used member of the
39 family due to its cavity size, availability, and low cost, even if its limited aqueous solubility often hinders its
40 successful application as solubilizing agent (Redenti et al., 2000).

41 Thanks to their vectorization ability and biocompatibility, CDs are of great interest in pharmaceuticals,
42 cosmetics, medicine, agriculture, food and textile industry (Bilensoy, 2011; Brewster and Loftsson, 2007;
43 Challa et al., 2005; Crini, 2014; Loftsson and Duchêne, 2007; Rasheed et al., 2008). Indeed, the
44 complexation may significantly improve the physical, chemical, and biological properties of a guest, namely
45 its aqueous solubility, dissolution rate, absorption, bioavailability and stability (Bilensoy, 2011; Brewster
46 and Loftsson, 1996; Diniz et al., 2018; Loftsson and Brewster, 2012; Wouessidjewe et al., 1999).
47 Additionally, the encapsulation in CDs has been advantageously exploited to reduce irritation and toxicity,
48 control the rate of release, and improve palatability and handling. CDs encapsulate also amphiphilic
49 compounds, including surfactants and several drugs (e.g. tricyclic antidepressants or phenothiazine
50 tranquilizers). As a result of the inclusion complex formation, the critical micelle concentration of the guest
51 can be increased. Another strong point of CDs is that they are chiral and can be used to differentiate
52 enantiomeric species through the formation of diastereomeric complexes (Dodziuk et al., 2004; Wenzel and
53 Chisholm, 2011). The enantioselective ability made CDs appealing materials for the determination of
54 enantiomeric purity of pharmaceuticals and as supramolecular chiral selectors for chromatographic
55 separations (Wang et al., 2019).

56 Given the benefits coming from the use of CDs in pharmaceutical chemistry and technology, biochemistry
57 and drug research, intense research activity grew around the study and characterization of CDs/drugs
58 inclusion complexes.

59 Tricyclic drugs are among the investigated compounds, and here we will focus on two of them, namely
60 amitriptyline (AMT) and cyclobenzaprine (CBZ). AMT and CBZ share a basic butterfly-like structure, with a
61 middle boat-like seven-membered ring C, fused to two adjacent aromatic rings, A and B, as wings, and
62 connected with an N,N-dimethyl-1-propanamino side chain via an exocyclic double bond at C5 (Fig. 1). The

63 presence of the alkylamine side chain gives AMT and CBZ a surfactant-like behaviour, which may result in
64 the formation of aggregates in aqueous solution.

65 AMT and CBZ are rather flexible and show inherent chirality (Dalla Cort et al., 2004), due to the bending of
66 the three-ring core and the exocyclic double bond that prevents the free rotation of the side chain with
67 respect to the ring system. As a result, they form diastereomeric inclusion complexes with β CD in aqueous
68 solutions (Castiglione et al., 2017).

69 AMT belongs to the family of tricyclic antidepressants (TCAs) and is widely used for the treatment of
70 depression (Cano et al., 2007). As all the first-generation TCAs, AMT suffers from several side-effects, such
71 as anti-arrhythmic, anti-cholinergic, cardiovascular and/or hyperthermia side effects (Ali et al., 2012). The
72 disadvantages related to the administration of AMT following a conventional therapeutic protocol (poor
73 water solubility, aggregation and concomitant side effects) can be mitigated if the drug is suitably vectored
74 to the organism with the help of CD as carrier excipient (Ali et al., 2012; Cano et al., 2007; Diniz et al., 2018;
75 Junquera et al., 2001).

76 CBZ is a muscle relaxant indicated in the relief of muscle spasms. In the presence of β CD, it forms freely
77 soluble and stable inclusion complexes, which allows to reduce the dose as well as the concomitant side
78 effects (Redenti et al., 2000; Szejtli, 1995).

79 The inclusion complexes of CDs with tricyclic drugs have received attention over the past decades (Ali et al.,
80 2012; Aree, 2020; Cano et al., 2007; Castiglione et al., 2017; Cruz et al., 2008; De Sousa et al., 2008;
81 Georgiou et al., 1999; Junquera et al., 2001; Kundu and Roy, 2017; Nishikawa and Kamimura, 2011;
82 Rajendiran et al., 2014; Redenti et al., 2000; Valsami et al., 1992). However, non-homogeneous results are
83 found in the literature. First, very different binding constants have been estimated. For instance, binding
84 constants of $13.2 \times 10^3 \text{ M}^{-1}$, 368 M^{-1} , or 569 M^{-1} have been reported for 1:1 complexes of doxepin in β CD
85 (Rajendiran et al., 2014; Valsami et al., 1992). For amitriptyline in β CD, association constant values range
86 from $23.9 \times 10^3 \text{ M}^{-1}$ to $3.2 \times 10^3 \text{ M}^{-1}$ (Junquera et al., 2001; Valsami et al., 1992). Moreover, different
87 geometries for inclusion complexes of tricyclic drugs have been proposed. For example, Junquera *et al.*
88 (2001) found that amitriptyline, imipramine and desipramine insert their side chain in the β CD cavity, while
89 the three cycles reside out of the apolar cavity. Contrarily, the formation of stable inclusion complexes
90 originating from insertion of the aromatic ring of doxepin and dothiepin in β CD's cavity was suggested by
91 Rajendiran *et al.* (2014). Kundu and Roy (2017) reported that nortriptyline and β CD form a 1:1 inclusion
92 complex with two plausible inclusion modes, the side chain and the tricyclic rings. Also, an equilibrium
93 among 1:2, 1:1, and 2:1 β CD/imipramine complexes, with possible inclusion of either the rings or the
94 aliphatic chain, was proposed (De Sousa et al., 2008). Castiglione *et al.* (2017) showed that CBZ and AMT
95 form 1:1 inclusion complexes with β CD, with the A ring embedded in the β CD cavity and the side chain


96 protruded from the O2'/O3'-side. A similar inclusion scenario in the β CD cavity was proposed by Aree
97 (2020) for nortriptyline and amitriptyline. According to their findings, the two tricyclic drugs insert the A
98 ring into the β CD cavity from the O2'/O3' side vertically and quite deeply to the O6'-side. The A ring
99 moieties are then kept in place by host-guest C5-H $\cdots\pi$ interactions with the β CD internal protons H5'.
100 Additionally, the inclusion induces conformational changes of β CD, with a narrowing of the O6' end to
101 optimally accommodate the A-ring in the cavity and a simultaneous widening of the O2'/O3' end to make
102 van der Waals contacts with the B-ring and the side chain (Aree, 2020).

103 It is then clear that the detailed description of tricyclic drugs / β CD inclusion structures still deserves
104 investigation. A deep understanding of the encapsulation process at the molecular level is crucial for a
105 rational design of CD/drug formulations. Next to a structural characterization, dynamic parameters such as
106 association constants and/or rotational mobility are essential to obtain a clear picture of the inclusion
107 complex and the association process (Cano et al., 2007).

108 Complexes between CDs and guest molecules can be investigated by a variety of methods, including UV-VIS
109 spectroscopy, fluorescence measurements, X-ray crystallography, calorimetry, NMR, electrochemistry,
110 separation techniques, and mass spectrometry. Out of these techniques, only X-ray crystallography and
111 NMR spectroscopy yield information on the inclusion complex on an atomic level. However, X-ray
112 crystallography gives a static view of the complex and depends on the availability of high-quality single
113 crystals. Contrarily, NMR measurements can be run in solution and allow to access dynamic properties
114 together with molecular structural information.

115 Here we apply NMR spectroscopy to study and characterize 1:1 inclusion complexes of the tricyclic drugs
116 amitriptyline and cyclobenzaprine with β CD. In most NMR studies, complexation-induced chemical shift
117 and nuclear Overhauser enhancement experiments are used to characterize the host-guest inclusion
118 complexes. We aim at demonstrating that very precise qualitative and quantitative information at the
119 molecular level can be accessed by combining several NMR techniques. AMT/ β CD and CBZ/ β CD have been
120 already studied by Castiglione *et al.* (2017): a 1:1 host-guest stoichiometry was determined using the Job's
121 plot and the analysis of intermolecular NOEs in the rotating frame (ROESY) was applied to describe the
122 inclusion geometry. In the present work, we first show that the enantiorecognition ability of β CD towards
123 the two inherently chiral molecules can be probed by ^{13}C NMR spectroscopy, with significant advantage
124 with respect to ^1H NMR. Then, diffusion Ordered Spectroscopy (DOSY) is applied to get the bound fraction
125 and the association constant. Finally, quantitative dynamic information on the inclusion complex in terms
126 of rotational correlation time and host-guest interactions are collected by measurements of non-selective,
127 selective and biselective spin-lattice relaxation times (T_1^{NS} , T_1^{SE} , and T_1^{BS}). We expect that the outcomes
128 will show that the characterization of CD/drug inclusion complexes from a physicochemical point of view

129 can constructively complement the conventional pharmacological and pharmacokinetic experiments, and
130 can shed light on the understanding of CD/drug formulations.



132 **Figure 1.** Structure and numbering of guest and host molecules investigated in this work.

133

134 2. Experimental

135 2.1 Materials and sample preparation

136 β -cyclodextrin (β CD) and D_2O were purchased from Sigma-Aldrich, while amitriptyline hydrochloride (AMT)
137 and cyclobenzaprine hydrochloride (CBZ) from Dipharma. The commercially available HCl salt form was
138 used for both drugs. All chemicals were used without further purification.

139 Samples AMT/ D_2O and CBZ/ D_2O were prepared dissolving the drug in D_2O for a concentration equal to
140 4.0mM. Samples containing β CD (AMT/ β CD/ D_2O and CBZ/ β CD/ D_2O) were prepared with a drug's
141 concentration equal to 4.7 and 4.0 mM, respectively, and a final host/guest molar ratio of 1:1. Note that
142 due to the presence of the alkylamine side chain, the drugs possess amphiphilic behaviour, which can result
143 in the formation of aggregates in aqueous solution at or above certain critical concentrations. Critical
144 aggregation concentration (cac) of the free AMT was found to be 33 mM or 43 mM (Ali et al., 2012;
145 Junquera et al., 2001), and is increased by addition of β CD, then we used concentrations well below the
146 cac.

147 Sample β CD/ D_2O was prepared dissolving β CD in D_2O at 9 mg/ml.

148

149 2.2 NMR experiments

150 The samples for NMR analysis were placed in standard 5 mm tubes. All NMR spectra were recorded at 298
151 K at 11.7 T using a Bruker NEO 500 spectrometer equipped with a 5 mm pulsed-field z-gradient BBFO probe
152 and a variable-temperature unit.

153 1D $^{13}\text{C}\{-^1\text{H}\}$ spectra were recorded using 65536 points and 12288 scans. Raw data were apodized by
154 multiplication with an exponential decay equivalent to 2.0 Hz line broadening.

155 HSQC spectra were recorded for samples AMT/ $\beta\text{CD}/\text{D}_2\text{O}$ and CBZ/ $\beta\text{CD}/\text{D}_2\text{O}$, using data matrices of 1024 (t_2)
156 x 1024 (t_1) complex data points. 8 or 16 transients were accumulated per increment, with 50% non-uniform
157 sampling (NUS). Raw data were processed by applying a cosine squared sine window functions in both
158 dimensions.

159 Self-diffusion coefficients were measured by Diffusion Ordered Spectroscopy (DOSY) experiments by
160 applying sine shaped pulsed magnetic field gradients along the z-direction up to a maximum strength of $G =$
161 53.5 G cm^{-1} . All of the experiments were performed using the bipolar pulse longitudinal eddy current delay
162 (BPPLD) pulse sequence, over a spectral width of 9 ppm for samples AMT/ D_2O and AMT/ $\beta\text{CD}/\text{D}_2\text{O}$, 10 ppm
163 for samples CBZ/ D_2O and CBZ/ $\beta\text{CD}/\text{D}_2\text{O}$, and 7 ppm for sample $\beta\text{CD}/\text{D}_2\text{O}$. The gradient strength (g) was
164 varied incremented in 32 steps from 2% to 95% of the maximum gradient strength in a linear ramp. The
165 parameters were chosen to obtain 95% signal attenuation for the slowest diffusion species at the last step
166 experiment. A total of 24 or 32 transients per increments was used for samples AMT/ D_2O , CBZ/ D_2O ,
167 AMT/ $\beta\text{CD}/\text{D}_2\text{O}$ and CBZ/ $\beta\text{CD}/\text{D}_2\text{O}$, and 8 transients per increments for sample $\beta\text{CD}/\text{D}_2\text{O}$. Values in the range
168 2.2-3.2 ms for the gradient duration (δ), and of 0.1 s for the diffusion delay (Δ) were applied. The baselines
169 of all arrayed spectra were corrected prior to processing the data. Data were processed using an
170 exponential filter in F_2 dimension (line broadening of 0.5 Hz) and integrals were used in calculating
171 relaxation times. Diffusion coefficients were computed from experimental raw data by using the Bruker
172 T_1/T_2 relaxation module. Taking into account the experimental S/N ratio, the accuracy of the measurements
173 is estimated at about 5%.

174 The spin-lattice relaxation rates were measured using data matrices of 16384 (t_2) x 16 (t_1) complex data
175 points with the inversion recovery (IR) $(180^\circ - \tau - 90^\circ - \text{acq})_n$ pulse sequence, having the initial 180° pulse
176 either non-selective, selective or biselective. In all experiments, the relaxation delays were set equal or
177 higher than 5 times the longest T_1 . All experiments were carried out over a spectral width of 9 ppm for AMT
178 and 10 ppm for CBZ, for various delay time τ . A total of 16 to 32 transients per increments were collected
179 for each experiment, depending on the S/N ratio. The selective inversion pulse was achieved by
180 replacement of the hard 180° pulse of the inversion-recovery sequence by a Gauss1.1000 shaped π -pulse
181 with a length ranging from 24 ms (corresponding to an excitation width of about 30 Hz) to 9 ms
182 (corresponding to an excitation width of about 80 Hz) and an attenuation power from 32 dB to 40 dB. The
183 biselective pulse was built prior to each experiment using the Bruker WaveMaker tool. The baselines of all
184 arrayed spectra were corrected prior to processing the data. Data were processed using an exponential
185 filter in F_2 dimension and integrals were used in calculating relaxation times. Relaxation times were
186 computed from experimental raw data by using the Bruker T_1/T_2 relaxation module with the standard one-

187 component fitting function. Taking into account the experimental S/N ratio and the standard deviation in
188 the analysis of T_1 values with both treatments, maximum errors are estimated to be 5%.

189

190

191

192 **3. Results and Discussion**


193 As anticipated in section 1 (Introduction), the stoichiometry and the geometry of the AMT/ β CD and
194 CBZ/ β CD inclusion complexes have been already investigated using ^1H NMR complexation-induced
195 chemical shifts and ROESY spectra, in a joint approach with X-ray diffraction and molecular dynamics
196 simulations.(Castiglione et al., 2017) Here we extend the NMR characterization of the same complexes
197 showing that valuable qualitative and quantitative information can be obtained integrating several NMR
198 techniques.

199 **3.1 Chiral recognition: the advantages of ^{13}C NMR spectroscopy**

200 ^1H spectra are usually the first NMR tool for the evaluation of the drug inclusion within the β CD cavity,
201 taking into account the variation induced by the complexation on the chemical shifts of both the CD and
202 drug protons. In the case of chiral complexed guests, some additional important structural features can be
203 outlined by the analysis of their ^1H NMR spectra. Indeed, CDs and their derivatives are effective chiral NMR
204 solvating agents and can hence discriminate between two enantiomers. This enantioselective recognition
205 ability has been demonstrated towards many molecules of pharmaceutical interest (Dodziuk et al., 2004;
206 Schneider et al., 1998; Wenzel and Chisholm, 2011). Similarly, upon inclusion of the inherently chiral drug
207 CBZ in β CD, the formation of two diastereomeric complexes can be testified by the peculiar modification of
208 its ^1H spectrum: the AB quartet corresponding to protons H9 and H10 splits into two AB quartets on passing
209 from the pure drug to the corresponding CBZ/ β CD complex (Fig. S1) (Castiglione et al., 2017).
210 Unfortunately, a chemical shift difference for other enantiomeric ^1H signals of CBZ and AMT cannot be
211 appreciated in their ^1H spectra (Fig. S1).

212 ^{13}C NMR is a helpful alternative method to investigate the inclusion process. Proton decoupled ^{13}C spectra
213 have been used to evaluate the encapsulation through complexation-induced variation of the chemical
214 shifts (Kundu and Roy, 2017), and they are particularly informative to verify chiral recognition
215 (Chankvetadze et al., 1995; Di Pietro et al., 2020). For instance, ^{13}C NMR shifts have been exploited for
216 chiral discrimination of some chiral antidepressant azepine-type drugs, showing larger differences than
217 proton shifts (Chankvetadze et al., 1995). Recently, we have also used $^{13}\text{C}\{-^1\text{H}\}$ spectra to demonstrate the
218 retained enantioselective recognition ability of β CD in a complex deep eutectic mixture composed of choline

219 chloride, urea and water (Di Pietro et al., 2020). Proton decoupled ^{13}C spectra acquired on all samples are
220 displayed in Figs. S2-S3. It can be seen that a number of ^{13}C NMR signals of AMT and CBZ are duplicated due
221 to the non-equivalence of complexation-induced chemical shifts of the diastereomeric complexes. Among
222 the aliphatic carbons, the signals corresponding to C12 of CBZ, C9 or C10 of AMT and C13 of both AMT and
223 CBZ, clearly split (Fig. S2). Splittings can be observed also for the majority of signals corresponding to
224 aromatic and quaternary carbons (see for instance C9, C10, C17 and C18 of CBZ in Fig. S3). The main
225 drawback of ^{13}C NMR experiments is that they require long experimental time, much longer than ^1H NMR
226 experiments. On the other hand, it is evident that they offer a broader spectral width with respect to ^1H
227 NMR, which translates into a better resolution and an easier assignment of signals (Dodziuk et al., 2004;
228 Silva, 2017). Interestingly, ^1H - ^{13}C HSQC correlation spectra can also be used to verify that ^{13}C NMR signals
229 are duplicated. Fig. 2 and Figs. S4-S5 show correlation peaks corresponding to selected carbons of AMT and
230 CBZ in samples AMT/ $\beta\text{CD}/\text{D}_2\text{O}$ and CBZ/ $\beta\text{CD}/\text{D}_2\text{O}$. A trivial case is represented by the peaks corresponding
231 to the C9-H9 and C10-H10 correlations in sample CBZ/ $\beta\text{CD}/\text{D}_2\text{O}$ (Fig. 2b, right): a clear differentiation is
232 visible in both ^1H and ^{13}C projections, which is confirmed by the cross peaks. The situation is different if one
233 considers the same nuclear pairs 9 and 10 in sample AMT/ $\beta\text{CD}/\text{D}_2\text{O}$. In this case the signals corresponding
234 to C9 and C10 are duplicated, whereas the difference in the chemical shift of protons H9 and H10 in the
235 two diastereomeric complexes is so tiny that cannot be appreciated in the ^1H spectrum. The HSQC
236 experiment (Fig. 2a, left) confirms the assignment of the carbon signals and uncovers the slight difference
237 in the proton dimension. The same holds for the C8-H8 correlation in the AMT/ βCD complex (Fig. 2a, right)
238 and for the C13-H13 correlation in the CBZ/ βCD complex (Fig. 2b, left). It is then clear that, even though the
239 enantiomeric ^1H signals mostly overlap, the wider spectral width on the carbon dimension makes it possible
240 to detect the non-equivalent carbon signals of the two diastereomeric complexes. This is a clear
241 demonstration of the higher performance of ^{13}C over ^1H NMR to unambiguously assess chiral recognition.



242

243 **Figure 2.** Enlargements of selected signals of 2D ^1H - ^{13}C HSQC correlation spectra corresponding to (a) C8, C9
 244 and C10 of AMT in sample AMT/ $\beta\text{CD}/\text{D}_2\text{O}$, and (b) C9, C10 and C13 of CBZ in sample CBZ/ $\beta\text{CD}/\text{D}_2\text{O}$.


245

246 3.2 Association constants: single-point diffusion measurements

247 ^1H NMR techniques were used to gather information on the dynamics of the inclusion complexes. It is
 248 worth remembering that in ^1H spectra signals of the two diastereomeric inclusion complexes are not
 249 distinct or, in case of non-equivalence, they overlap. Therefore, in the following relaxation and diffusion
 250 analysis, each signal is considered as an average of both diastereomeric complexes.

251 An advantageous NMR technique used for the determination of association constants in CD inclusion
252 complexes is diffusion NMR (Barhoum et al., 2016; Fielding, 2007; Pagès et al., 2017; Uccello-Barretta et al.,
253 2005). The rationale behind is that the translational diffusion coefficient (D) of a molecule is proportional to
254 its effective size and shape. Broadly speaking, this means that a small molecule diffuses faster than a large
255 one. Analogously, the encapsulation of a small drug into the cavity of a large cyclodextrin leads to a
256 decrease of the guest diffusion coefficient. An easy way to illustrate this concept is via a DOSY (Diffusion
257 Ordered Spectroscopy) experiment, where the chemical shift is plotted in one dimension and the diffusion
258 coefficient in the other one (Morris and Johnson, 1992). Fig. 3 displays DOSY maps acquired for AMT and
259 CBZ as free drugs or complexed with β CD. As a result of the inclusion in the β CD's cavity, the diffusion of
260 both drugs in the samples with β CD (in red) is slower than in the corresponding samples without β CD (in
261 green for AMT and blue for CBZ). More in detail, AMT and CBZ tend to have similar mobilities and
262 diffusivities close to β CD, as also observed for other tricyclic antidepressants (De Sousa et al., 2008).

263



264

265 **Figure 3.** DOSY maps acquired for (a) samples AMT/ D_2O (in green) and AMT/ β CD/ D_2O (in red) and (b)
266 CBZ/ D_2O (in blue) and CBZ/ β CD/ D_2O (in red).

267

268 Following a commonly used methodology (see Theoretical toolbox in the SI for more details) (Brand et al.,
269 2005; Cohen et al., 2005; Di Pietro et al., 2019; Lis-Cieplak et al., 2014; Uccello-Barretta et al., 2005), DOSY
270 measurements can be exploited to determine the mole fraction of the bound guest x_G^{bound} . Basically, when

271 the host and guest are tightly bound in a complex, they diffuse as a single entity and display the same
 272 diffusion coefficient. In this case x_G^{bound} is equal to 1. When the association is weak or negligible, x_G^{bound} is
 273 equal to 0 and the diffusion coefficients of the host and the guest remain unchanged. For any other case, in
 274 the fast exchange limit, the observed diffusion coefficient D_G^{obs} is a weighted average of the diffusion
 275 coefficient of the free and bound states (D_G^{free} and D_G^{bound} , respectively) (Brand et al., 2005; Cohen et al.,
 276 2005; Uccello-Barretta et al., 2005):

$$D_G^{obs} = (1 - x_G^{bound})D_G^{free} + x_G^{bound}D_G^{bound} \quad (1)$$

277 As guest molecules are typically much smaller than cyclodextrins, one can assume that D_G^{bound} will be very
 278 similar to the diffusion coefficient of the host (D_H). Hence, x_G^{bound} can be determined as follows (Brand et
 279 al., 2005; Cohen et al., 2005; Uccello-Barretta et al., 2005):

$$x_G^{bound} = \frac{D_G^{obs} - D_G^{free}}{D_H - D_G^{free}} \quad (2)$$

280 From x_G^{bound} , it is then possible to determine the association constant K_a (Brand et al., 2005; Cohen et al.,
 281 2005; Uccello-Barretta et al., 2005):

$$K_a = \frac{x_G^{bound}}{(1 - x_G^{bound})([H]_0 - x_G^{bound}[G]_0)} \quad (3)$$

282 where $[H]_0$ and $[G]_0$ are the total concentrations of host and guest, respectively.

283 Practically speaking, D_G^{obs} and D_G^{free} of AMT and CBZ are measured in the equimolar host-guest mixtures
 284 (samples AMT/ β CD/ D_2O and CBZ/ β CD/ D_2O) and in the absence of the host (samples AMT/ D_2O and
 285 CBZ/ D_2O), respectively. D_H is measured for the cyclodextrin alone (sample β CD/ D_2O). In this way, it is
 286 possible to determine x_G^{bound} and K_a from single DOSY experiments, without the need of titrations. We
 287 have recently reported the diffusion coefficients of AMT and CBZ together with the calculated x_G^{bound} (Di
 288 Pietro et al., 2020). Here the K_a are also calculated and listed in Table 1. Taking into account the inaccuracy
 289 in the calculations coming from the different approximations and the experimental errors both in sample
 290 preparation and in the acquisition and treatment of the experimental data, an error equal to 5% is
 291 estimated. A very similar inclusion behaviour can be observed for the two drugs, with most of the drug in
 292 the complexed state (mole fraction of the bound drug equal to 0.88 for AMT and 0.84 for CBZ). The values
 293 of the association constants obtained for both complexes are relatively high (in the order of 10^3 M^{-1}) and
 294 fall within an optimum range from a pharmaceutical point of view. Indeed, binding constants ranging from
 295 200 to 10000 M^{-1} are considered suitable for the encapsulation of drugs by cyclodextrins (Cano et al.,
 296 2007). β CD is hence an appropriate vector for the drugs amitriptyline and cyclobenzaprine.

297

298 **Table 1.** Diffusion coefficients, molar fraction of the bound guest x_G^{bound} and association constant K_a
 299 determined for AMT and CBZ. Maximum errors are estimated to be 5%

Guest	D_G^{obs} [10^{-10}] (m^2s^{-1})	D_G^{free} [10^{-10}] (m^2s^{-1})	D_H [10^{-10}] (m^2s^{-1})	x_G^{bound}	K_a [10^3] (M^{-1})
AMT	2.5 ± 0.1^a	4.2 ± 0.2^a	2.2 ± 0.1^a	0.88 ± 0.04^a	8.2 ± 0.4
CBZ	2.7 ± 0.1^a	4.3 ± 0.2^a	2.3 ± 0.1^a	0.84 ± 0.07^a	8.5 ± 0.4

300 ^a Data from Di Pietro et al. (2020)

301 It has been argued that the previous methodology may not be fully reliable for medium-sized host
 302 molecules, including cyclodextrins (see SI) (Brand et al., 2005; Cameron and Fielding, 2001). Briefly, the
 303 method relies on the assumption that, when a small guest molecule binds to a large host molecule, the
 304 diffusion coefficient of the host is only insignificantly affected by the complexation. Therefore, the diffusion
 305 coefficient of the bound guest D_G^{bound} and the observed diffusion coefficient of the CD host, D_H , are
 306 assumed to be equal. This approximation is valid for most studies involving small molecules binding to
 307 macromolecules, but may not be true for cyclodextrins and other medium-sized host molecules. To face
 308 this criticism we acquired a series of diffusion experiments with solutions having different host:guest mole
 309 ratios (Cameron and Fielding, 2001). As discussed in the SI, we found that the apparent diffusion coefficient
 310 measured for β CD in all samples was substantially constant within the experimental error over the full
 311 range of concentrations. Hence, in the context of the present study the assumption that $D_G^{bound} = D_H$ can
 312 be considered valid and the single point approximation appropriate for the evaluation of K_a .

313

314 **3.3 Correlation times and fractional binding: non-selective, selective and biselective spin-lattice** 315 **measurements**

316 The application of 1H relaxation experiments to study aggregation, interactions and/or binding processes
 317 with macromolecules, including cyclodextrins, is well known (De Sousa et al., 2008; Fielding, 2007; Li et al.,
 318 2007; Reddy et al., 2015; Rossi et al., 2001; Schneider et al., 1998; Tinoco and Figueroa-Villar, 1999; Tošner
 319 et al., 2006). Recently, the use of non-selective (R_1^{NS}), selective (R_1^{SE}) and bi-selective (R_1^{BS}) spin-lattice
 320 relaxation rates was revised as a tool to derive informative dynamical parameters characterizing the
 321 inclusion complexes formed by two drugs, paracetamol and aspirin, with β CD (Kumar et al., 2017). We also
 322 demonstrated that non-selective and selective relaxation T_1 experiments can successfully be applied to get
 323 information on the rotational motion of encapsulated drugs in complex media such as deep eutectic


324 systems (Di Pietro et al., 2020).

325 Following the methodology by Kumar *et al.* (2017), in the present work we measured and analysed R_1^{NS} ,
326 R_1^{SE} and R_1^{BS} for the complexes of AMT and CBZ with β CD to access valuable dynamical parameters, namely
327 the molecular rotational correlation times (τ_c) and the cross-relaxation rates (σ_{ij}) of drugs encapsulated in
328 β CD cavities. A detailed theoretical treatment is given in the SI. Here, we directly focus on the dynamical
329 results with the aim of showing how the method allows to get meaningful insights regarding the relaxation
330 mechanism of the drug/ β CD complexes and the contribution of other relaxation processes to the
331 dipole–dipole interactions.

332 Briefly, the molecular rotational correlation time τ_c of the encapsulated drug, which is the average time
333 needed for the molecule to rotate by approximately 1 radian during the isotropic tumbling in the liquid
334 state, can be derived by measuring the R_1^{NS}/R_1^{SE} ratio within the initial rate approximation (Fielding, 2007;
335 Freeman et al., 1974; Hall and Hill, 1976; Tinoco and Figueroa-Villar, 1999):

$$\frac{R_1^{NS}}{R_1^{SE}} = \left[\frac{3\tau_c}{1 + \omega_0^2\tau_c^2} + \frac{12\tau_c}{1 + 4\omega_0^2\tau_c^2} \right] / \left[\frac{3\tau_c}{1 + \omega_0^2\tau_c^2} + \frac{6\tau_c}{1 + 4\omega_0^2\tau_c^2} + \tau_c \right] \quad (4)$$

336 Both the R_1^{NS}/R_1^{SE} ratio and τ_c are valuable indicators of the motional regime of the drug. Results obtained
337 for AMT/ β CD and CBZ/ β CD complexes are summarized in Fig. 4 and Table S1. Note that novel results are
338 integrated with data previously reported (Di Pietro et al., 2020). From the experimental standpoint, to
339 properly measure selective T_1 relaxation times the ^1H spectrum has to be sufficiently dispersed so that the
340 inversion pulse can be applied selectively to the chosen resonances (Freeman et al., 1974). Here we
341 selected protons H8, H11, H12 and H14 for AMT and protons H9,10, H11 and H13 for CBZ. As discussed
342 previously (Di Pietro et al., 2020), for protons H8 and H12 of AMT and for protons H9,10 of CBZ the
343 R_1^{NS}/R_1^{SE} ratio in D_2O is in the range 1.5-1.05, indicating a fast to intermediate motion regime for 500 MHz
344 ^1H frequency (Kumar et al., 2017; Tinoco and Figueroa-Villar, 1999). In the presence of β CD values close to 1
345 can be observed, which is symptomatic of intermediate regime. The same holds for the novel data obtained
346 for proton H11 of AMT and CBZ. The slowdown in the dynamics of the drug suggested by the R_1^{NS}/R_1^{SE} ratio
347 can be also quantified in terms of rotational correlation time τ_c , which is inversely proportional to the
348 degree of molecular mobility. Indeed, we found for the free drugs values of τ_c in the range 0.20-27 ns.
349 Upon addition of β CD, the encapsulation in the β CD cavity slows down the rotational mobility of the drugs,
350 so that τ_c values increase to 0.30-0.36 ns. As already reported (Di Pietro et al., 2020), proton H14 of AMT
351 shows a peculiar behaviour, as the R_1^{NS}/R_1^{SE} ratio close to unity both for the free and the encapsulated
352 drug. This was ascribed to the fact that the local rotational motion of the terminal methyl groups is not
353 markedly affected by formation of the inclusion complex (Di Pietro et al., 2020). A somehow intermediate
354 situation is experienced by proton H13 of CBZ, as testified by the small increase of τ_c (from 0.27 to 0.30 ns).



355

356 **Figure 4.** Selected τ_C values (in ns) obtained for (a) amitriptyline (AMT) and its complex with β CD, and (b)
 357 cyclobenzaprine (CBZ) and its complex β CD. Maximum errors are estimated to be 5% of the value.


358

359 To go further, we run bi-selective inversion recovery experiments in order to extract another valuable
 360 dynamical parameter, that is the fractional contribution to relaxation of a proton i via dipolar interaction
 361 with a proton j that is simultaneously inverted (see SI) (Hall and Hill, 1976; Kumar et al., 2017):

$$f_{ij}^i = \frac{2 \cdot [R_1^{\text{BS}}(ij) - R_1^{\text{SE}}(i)]}{R_1^{\text{SE}}(i)} \quad (5)$$

362 Using Eq. (5) we quantified the fractional contribution to the cross-relaxation rate of protons H6, H8, H11,
 363 H12 and H14 of AMT and protons H9,10 and H11 of CBZ, due to intermolecular dipolar interactions with
 364 protons H1' and H5' of β CD in the inclusion complexes. Unfortunately, we could not select the same
 365 protons for the two drugs, since H9,10 of AMT and H6, H8, H12 and H14 of CBZ are not isolated enough to
 366 be selectively inverted and guarantee an accurate T_1 measurement. Results are reported in Fig. 5 and Table
 367 S2. f_{ij}^i enclose information on spatial proximity, i.e. the higher the f_{ij}^i value, the closer the proton pair ij . In
 368 the sample AMT/ β CD/ D_2O the highest f_{ij}^i value with respect to H1' of β CD was calculated for H11, followed
 369 by H12 and H14. H6 and H8 showed quite small values, indicating they are located further from H1' of β CD.
 370 Contrarily, H6 and H8 show the highest f_{ij}^i values with respect to proton H5' of β CD, suggesting a close
 371 proximity between the proton pair and hence confirming the insertion of the aromatic ring in the β CD
 372 cavity. A similar picture can be derived for sample CBZ/ β CD/ D_2O , even if only data for protons H9,10 and
 373 H11 were accessible. The findings of the bi-selective T_1 measurements alone are not exhaustive to fully
 374 describe the geometry of inclusion and undoubtedly assess whether the drug molecule enters the cavity of
 375 cyclodextrin from the large opening or the small one. Nevertheless, they are in contrast with the
 376 description suggested by Junquera *et al.* (2001) for amitriptyline, with the insertion of the side chain in the
 377 β CD cavity and the three cycles out of the apolar cavity. Our experimental findings are instead consistent
 378 with the inclusion geometry previously described by Castiglione *et al.* (2017) and Aree (2020), with the A

379 ring inserted into the β CD cavity from the wider opening, and the seven-membered ring, the
380 alkylammonium chain and the other aromatic ring protruding out of the cavity.



381

382 **Figure 5.** Fractional contribution to cross-relaxation of selected protons of (a) amitriptyline (AMT) and (b)
383 cyclobenzaprine (CBZ), via dipolar interaction with proton H1' (bar diagrams on the top) or H5' (bar
384 diagrams on the bottom) of β CD. Maximum errors are estimated to be 10% of the value.

385

386 4. Conclusions

387 A thorough physicochemical characterization of the interaction and binding between a drug and a potential
388 carrier is highly recommendable for an appropriate controlled release. Here, we exploited multiple NMR
389 techniques to deeply investigate the encapsulation of two tricyclic drugs, amitriptyline (AMT) and
390 cyclobenzaprine (CBZ), in β -cyclodextrin (β CD).

391 As AMT and CBZ are inherently chiral and are used as racemic mixture, diastereomeric inclusion complexes
392 are formed upon encapsulation in the cavity of the homochiral β CD. Here, ^{13}C NMR was used to
393 unambiguously assess chiral recognition, demonstrating a higher performance over ^1H NMR.

394 The mole fraction of the bound drug and the association constant have been derived through diffusion
395 experiments, whereas the combination of non-selective, selective and bi-selective relaxation spectra gave
396 insights into the rotational motion of the complexed drug and the spatial proximity of selected proton
397 pairs.

398 Overall, the different NMR methods applied confirm the geometry of inclusion described by Castiglione *et*
399 *al.* (2017), with an aromatic ring system inserted into the β CD cavity, and the seven-membered ring, the
400 alkylammonium chain and the other aromatic ring protruding out of the cavity. Next to it, in the present
401 work we demonstrated the potential of NMR spectroscopy for a comprehensive characterization of
402 host/guest complexes: each NMR experiment, namely 1D and 2D carbon spectra, PFG NMR and T_1
403 measurements, provide single pieces of the puzzle, which combined together reinforce themselves and give
404 access to the whole structural and dynamic picture. Such a characterization of CD/drug inclusion complexes
405 from a physicochemical point of view can constructively complement the conventional pharmacological
406 and pharmacokinetic experiments, shedding light on the understanding of CD/drug formulations. An added
407 value is the possibility to extend the methodology not only to other native and substituted cyclodextrins,
408 but also to other supramolecules and macrocyclic compounds, such as calixarenes.

409

410

411 **Supporting Information**

412 The following files are available:

413 1D $^{13}\text{C}\{-^1\text{H}\}$ and $^1\text{H}\text{-}^{13}\text{C}$ HSQC spectra, theoretical toolbox and method validation of diffusivity
414 measurements, theoretical toolbox of T_1 measurements, tables of T_1^{NS} , T_1^{SE} , $R_1^{\text{NS}}/R_1^{\text{SE}}$ ratio, τ_C and f_{ij}^i
415 values (PDF)

416

417 **Corresponding Author**

418 * Dr. Maria Enrica Di Pietro. Phone +39 02 2399 3045. Email mariaenrica.dipietro@polimi.it

419 * Prof. Andrea Mele. Phone +39 02 2399 3006. Email andrea.mele@polimi.it

420

421 **Declaration of interest**

422 None

423

424 **Funding**

425 This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-
426 profit sectors.

427

428 **Acknowledgment**

429 MEDP thanks Politecnico di Milano for her postdoctoral fellowship in the framework of the “MSCA EF
430 Master Class 2018” funding programme.

431

432 **References**

433 Ali, M.S., Rub, M.A., Khan, F., Al-Lohedan, H.A., Kabir-Ud-Din, 2012. Interaction of amphiphilic drug
434 amitriptyline hydrochloride with β -cyclodextrin as studied by conductometry, surface tensiometry and
435 viscometry. *J. Mol. Liq.* 167, 115–118. <https://doi.org/10.1016/j.molliq.2012.01.004>

436 Aree, T., 2020. β -Cyclodextrin encapsulation of nortriptyline HCl and amitriptyline HCl: Molecular insights
437 from single-crystal X-ray diffraction and DFT calculation. *Int. J. Pharm.* 575, 118899–118908.
438 <https://doi.org/10.1016/j.ijpharm.2019.118899>

439 Barhoum, S., Palit, S., Yethiraj, A., 2016. Diffusion NMR studies of macromolecular complex formation,
440 crowding and confinement in soft materials. *Prog. Nucl. Magn. Reson. Spectrosc.* 94–95, 1–10.
441 <https://doi.org/10.1016/j.pnmrs.2016.01.004>

442 Bilensoy, E. (Ed.), 2011. *Cyclodextrins in Pharmaceuticals, Cosmetics, and Biomedicine: Current and Future*
443 *Industrial Applications*. Wiley.

444 Brand, T., Cabrita, E.J., Berger, S., 2005. Intermolecular interaction as investigated by NOE and diffusion
445 studies. *Prog. Nucl. Magn. Reson. Spectrosc.* 46, 159–196.
446 <https://doi.org/10.1016/j.pnmrs.2005.04.003>

447 Brewster, M.E., Loftsson, T., 2007. Cyclodextrins as pharmaceutical solubilizers. *Adv. Drug Deliv. Rev.* 59,
448 645–666. <https://doi.org/10.1016/j.addr.2007.05.012>

449 Brewster, M.E., Loftsson, T., 1996. Pharmaceutical applications of cyclodextrins . 1 . Drug solubilization and
450 stabilization. *J. Pharm. Sci.* 85, 1017–1025.

451 Cameron, K.S., Fielding, L., 2001. NMR diffusion spectroscopy as a measure of host-guest complex

452 association constants and as a probe of complex size. *J. Org. Chem.* 66, 6891–6895.
453 <https://doi.org/10.1021/jo010081x>

454 Cano, J., Rodriguez, A., Aicart, E., Junquera, E., 2007. Temperature effect on the complex formation
455 between tricyclic antidepressant drugs (amitriptyline or imipramine) and hydroxypropyl- β -
456 cyclodextrin in water. *J. Incl. Phenom. Macrocycl. Chem.* 59, 279–285.
457 <https://doi.org/10.1007/s10847-007-9328-x>

458 Castiglione, F., Ganazzoli, F., Malpezzi, L., Mele, A., Panzeri, W., Raffaini, G., 2017. Inclusion complexes of β -
459 cyclodextrin with tricyclic drugs: An X-ray diffraction, NMR and molecular dynamics study. *Beilstein J.*
460 *Org. Chem.* 13, 714–719. <https://doi.org/10.3762/bjoc.13.70>

461 Challa, R., Ahuja, A., Ali, J., Khar, R.K., 2005. Cyclodextrins in drug delivery: An updated review. *AAPS*
462 *PharmSciTech* 6, 329–357. <https://doi.org/10.1208/pt060243>

463 Chankvetadze, B., Endresz, G., Bergenthal, D., Blaschke, G., 1995. Enantioseparation of mianserine
464 analogues using capillary electrophoresis with neutral and charged cyclodextrin buffer modifiers 13C
465 NMR study of the chiral recognition mechanism. *J. Chromatogr. A* 717, 245–253.
466 [https://doi.org/10.1016/0021-9673\(95\)00489-4](https://doi.org/10.1016/0021-9673(95)00489-4)

467 Cohen, Y., Avram, L., Frish, L., 2005. Diffusion NMR spectroscopy in supramolecular and combinatorial
468 chemistry : An old parameter — New insights. *Angew. Chemie - Int. Ed.* 44, 520–554.
469 <https://doi.org/10.1002/anie.200300637>

470 Crini, G., 2014. Review : A history of cyclodextrins. *Chem. Rev.* 114, 10940–10975.
471 <https://doi.org/10.1021/cr500081p>

472 Cruz, J.R., Becker, B.A., Morris, K.F., Larive, C.K., 2008. NMR characterization of the host-guest inclusion
473 complex between β -cyclodextrin and doxepin. *Magn. Reson. Chem.* 46, 838–845.
474 <https://doi.org/10.1002/mrc.2267>

475 Dalla Cort, A., Mandolini, L., Pasquini, C., Schiaffino, L., Chimica, D., Sapienza, U. La, Roma, B., 2004.
476 “Inherent chirality” and curvature. *New J. Chem.* 28, 1198–1199.

477 De Sousa, F.B., Leite Denadai, Â.M., Lula, I.S., Nascimento, C.S., Fernandes Neto, N.S.G., Lima, A.C., De
478 Almeida, W.B., Sinisterra, R.D., 2008. Supramolecular self-assembly of cyclodextrin and higher water
479 soluble guest: Thermodynamics and topological studies. *J. Am. Chem. Soc.* 130, 8426–8436.
480 <https://doi.org/10.1021/ja801080v>

481 Di Pietro, M.E., Colombo Dugoni, G., Ferro, M., Mannu, A., Castiglione, F., Costa Gomes, M., Fourmentin, S.,
482 Mele, A., 2019. Do cyclodextrins encapsulate volatiles in deep eutectic systems? *ACS Sustain. Chem.*

483 Eng. 7, 17397–17405. <https://doi.org/10.1021/acssuschemeng.9b04526>

484 Di Pietro, M.E., Ferro, M., Mele, A., 2020. Drug encapsulation and chiral recognition in deep eutectic
485 solvents/ β -cyclodextrin mixtures. *J. Mol. Liq.* 311, 113279.
486 <https://doi.org/10.1016/j.molliq.2020.113279>

487 Diniz, T.C., Pinto, T.C.C., Menezes, P. dos P., Silva, J.C., Teles, R.B. de A., Ximenes, R.C.C., Guimarães, A.G.,
488 Serafini, M.R., Araújo, A.A. de S., Quintans Júnior, L.J., Almeida, J.R.G. da S., 2018. Cyclodextrins
489 improving the physicochemical and pharmacological properties of antidepressant drugs: a patent
490 review. *Expert Opin. Ther. Pat.* 28, 81–92. <https://doi.org/10.1080/13543776.2017.1384816>

491 Dodziuk, H., Koźmiński, W., Ejchart, A., 2004. NMR studies of chiral recognition by cyclodextrins. *Chirality*
492 16, 90–105. <https://doi.org/10.1002/chir.10304>

493 Fielding, L., 2007. NMR methods for the determination of protein-ligand dissociation constants. *Prog. Nucl.*
494 *Magn. Reson. Spectrosc.* 51, 219–242. <https://doi.org/10.1016/j.pnmrs.2007.04.001>

495 Freeman, R., Hill, H.D.W., Tomlinson, B.L., Hall, L.D., 1974. Dipolar contribution to NMR spin-lattice
496 relaxation of protons. *J. Chem. Phys.* 61, 4466–4473. <https://doi.org/10.1063/1.1681764>

497 Georgiou, M.E., Georgiou, C.A., Koupparis, M.A., 1999. Rapid automated spectrophotometric competitive
498 complexation studies of drugs with cyclodextrins using the flow injection gradient technique: Tricyclic
499 antidepressant drugs with α -cyclodextrin. *Analyst* 124, 391–396. <https://doi.org/10.1039/a808426b>

500 Hall, L.D., Hill, H.D.W., 1976. Spin-lattice relaxation of protons. A general, quantitative evaluation of
501 contributions from the intramolecular dipole-dipole mechanism. *J. Am. Chem. Soc.* 98, 1269–1270.
502 <https://doi.org/10.1016/b978-0-408-01434-2.50020-6>

503 Junquera, E., Romero, J.C., Aicart, E., 2001. Behavior of tricyclic antidepressants in aqueous solution: Self-
504 aggregation and association with β -cyclodextrin. *Langmuir* 17, 1826–1832.
505 <https://doi.org/10.1021/la000819q>

506 Kumar, D., Krishnan, Y., Paranjothy, M., Pal, S., 2017. Analysis of molecular interaction of drugs within β -
507 cyclodextrin cavity by solution-state NMR relaxation. *J. Phys. Chem. B* 121, 2864–2872.
508 <https://doi.org/10.1021/acs.jpcc.6b11704>

509 Kundu, M., Roy, M.N., 2017. Preparation, interaction and spectroscopic characterization of inclusion
510 complex of a cyclic oligosaccharide with an antidepressant drug. *J. Incl. Phenom. Macrocycl. Chem.* 89,
511 177–187. <https://doi.org/10.1007/s10847-017-0745-1>

512 Kurkov, S. V., Loftsson, T., 2013. Cyclodextrins. *Int. J. Pharm.* 453, 167–180.
513 <https://doi.org/10.1016/j.ijpharm.2012.06.055>

- 514 Li, Y., Yin, G., Wei, W., Wang, H., Jiang, S., Zhu, D., Du, W., 2007. Interactions of Lycopodium alkaloids with
515 acetylcholinesterase investigated by ¹H NMR relaxation rate. *Biophys. Chem.* 129, 212–217.
516 <https://doi.org/10.1016/j.bpc.2007.05.020>
- 517 Lis-Cieplak, A., Sitkowski, J., Kolodziejcki, W., 2014. Comparative proton nuclear magnetic resonance studies
518 of amantadine complexes formed in aqueous solutions with three major cyclodextrins. *J. Pharm. Sci.*
519 103, 274–282. <https://doi.org/10.1002/jps.23802>
- 520 Loftsson, T., Brewster, M.E., 2012. Cyclodextrins as functional excipients: Methods to enhance
521 complexation efficiency. *J. Pharm. Sci.* 101, 3019–3032. <https://doi.org/10.1002/jps>
- 522 Loftsson, T., Duchêne, D., 2007. Cyclodextrins and their pharmaceutical applications. *Int. J. Pharm.* 329, 1–
523 11. <https://doi.org/10.1016/j.ijpharm.2006.10.044>
- 524 Morris, K.F., Johnson, C.S.J., 1992. Diffusion-ordered two-dimensional nuclear magnetic resonance
525 spectroscopy. *J. Am. Chem. Soc.* 114, 3139–3141.
- 526 Nishikawa, S., Kamimura, E., 2011. Dynamic characteristic of amitriptyline in water by ultrasonic relaxation
527 method and molecular orbital calculation. *J. Phys. Chem. A* 115, 535–539.
528 <https://doi.org/10.1021/jp1107729>
- 529 Pagès, G., Gilard, V., Martino, R., Malet-Martino, M., 2017. Pulsed-field gradient nuclear magnetic
530 resonance measurements (PFG NMR) for diffusion ordered spectroscopy (DOSY) mapping. *Analyst*
531 142, 3771–3796. <https://doi.org/10.1039/c7an01031a>
- 532 Rajendiran, N., Sankaranarayanan, R.K., Saravanan, J., 2014. A study of supramolecular host-guest
533 interaction of dothiepin and doxepin drugs with cyclodextrin macrocycles. *J. Mol. Struct.* 1067, 252–
534 260. <https://doi.org/10.1016/j.molstruc.2014.03.051>
- 535 Rasheed, A., Kumar C.K., A., Sravanthi, V.V.N.S.S., 2008. Cyclodextrins as drug carrier molecule: A review.
536 *Sci. Pharm.* 76, 567–598. <https://doi.org/10.3797/scipharm.0808-05>
- 537 Reddy, R.R., Phani Kumar, B.V.N., Shanmugam, G., Madhan, B., Mandal, A.B., 2015. Molecular level insights
538 on collagen-polyphenols interaction using spin-relaxation and saturation transfer difference NMR. *J.*
539 *Phys. Chem. B* 119, 14076–14085. <https://doi.org/10.1021/acs.jpcc.5b07911>
- 540 Redenti, E., Szente, L., Szejtli, J., 2000. Drug/cyclodextrin/hydroxy acid multicomponent systems. Properties
541 and pharmaceutical applications. *J. Pharm. Sci.* 89, 1–8.
- 542 Rossi, C., Bonechi, C., Martini, S., Ricci, M., Corbini, G., Corti, P., Donati, A., 2001. Ligand-macromolecule
543 complexes: Affinity index determination by selective nuclear relaxation analysis. *Magn. Reson. Chem.*
544 39, 457–462. <https://doi.org/10.1002/mrc.876>

545 Schneider, H.-J., Hacket, F., Rüdiger, V., Ikeda, H., 1998. NMR studies of cyclodextrins and cyclodextrin
546 complexes. *Chem. Rev.* 98, 1755–1786. <https://doi.org/10.1021/cr970019t>

547 Silva, M.S., 2017. Recent advances in multinuclear NMR spectroscopy for chiral recognition of organic
548 compounds. *Molecules* 22. <https://doi.org/10.3390/molecules22020247>

549 Szejtli, J., 1995. Selectivity/structure correlation in cyclodextrin chemistry. *Supramol. Chem.* 6, 217–223.
550 <https://doi.org/10.1080/10610279508032537>

551 Tinoco, L.W., Figueroa-Villar, J.D., 1999. Determination of correlation times from selective and non-
552 selective spin-lattice relaxation rates and their use in drug-drug and drug-albumin interaction studies.
553 *J. Braz. Chem. Soc.* 10, 281–286. <https://doi.org/10.1590/S0103-50531999000400005>

554 Tošner, Z., Aski, S.N., Kowalewski, J., 2006. Rotational dynamics of adamantanecarboxylic acid in complex
555 with β -cyclodextrin. *J. Incl. Phenom. Macrocycl. Chem.* 55, 59–70. [https://doi.org/10.1007/s10847-](https://doi.org/10.1007/s10847-005-9019-4)
556 [005-9019-4](https://doi.org/10.1007/s10847-005-9019-4)

557 Uccello-Barretta, G., Balzano, F., Paolino, D., Ciaccio, R., Guccione, S., 2005. Combined NMR-
558 crystallographic and modelling investigation of the inclusion of molsidomine into α -, β - and γ -
559 cyclodextrins. *Bioorganic Med. Chem.* 13, 6502–6512. <https://doi.org/10.1016/j.bmc.2005.07.009>

560 Valsami, G.N., Koupparis, M.A., Macheras, P.E., 1992. Complexation studies of cyclodextrins with tricyclic
561 antidepressants using ion-selective electrodes. *Pharm. Res.* 9, 94–100.

562 Wang, S., Li, L., Xiao, Y., Wang, Y., 2019. Recent advances in cyclodextrins-based chiral-recognizing
563 platforms. *Trends Anal. Chem.* 121, 115691.

564 Wenzel, T.J., Chisholm, C.D., 2011. Using NMR spectroscopic methods to determine enantiomeric purity
565 and assign absolute stereochemistry. *Prog. Nucl. Magn. Reson. Spectrosc.* 59, 1–63.
566 <https://doi.org/10.1016/j.pnmrs.2010.07.003>

567 Wouessidjewe, D., Ponchel, G., Duchene, D., 1999. Cyclodextrins and carrier systems. *J. Control. Release* 62,
568 263–268.

569

Declaration of interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

*Credit Author Statement

Maria Enrica Di Pietro: Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Validation; Visualization; Writing - original draft; Writing - review & editing.

Monica Ferro: Conceptualization; Investigation; Writing - review & editing.

Andrea Mele: Conceptualization; Supervision; Writing - review & editing.

Supplementary Material

[Click here to download Supplementary Material: IntJPharm_bCD-drugs_Special-Issue_SI_rev2.pdf](#)